3Vote!
MarketIntelligenceCenter.com (Free subscription) | 7 hours ago
AstraZeneca (NYSE: AZN) closed yesterday at $45.40. So far the stock has hit a 52-week low of $29.96 and 52-week high of $47.61. AstraZeneca stock has been showing support around 44.81 and resistance in the 46.13 range. Technical indicators for the stock are Bullish and S&P gives AZN a neutral 3 STAR (out of 5) hold rating. AZN appears on the Investors Observer Hedged Dividend Income list. For...
+Vote!
thepharmaletter.com (Free subscription) | yesterday
The US Court of Appeals for the First Circuit upheld an earlier District Court ruling on November 20, approving a $24 million settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against Anglo-Swedish drug major AstraZeneca.
+Vote!
thepharmaletter.com (Free subscription) | 7 hours ago
Over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by the uptake of three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/AstraZeneca/Takeda, says a new report from research and advisory firm Decision Resources.
3Vote!
Fitness Watch (Free subscription) | yesterday
Yet another reason to stay/get fit . "Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke. The Food and Drug Administration said the stomach-soothing drugs Prilosec and Nexium cut in half the blood-thinning effect of Plavix, known generically...
3Vote!
Forex Analytics (Free subscription) | 22/11/2009
Pharmaceutical company AstraZeneca plc (AZN, AZN.L) said Thursday it has submitted has New Drug Application for ticagrelor to the U.S. Food and Drug Administration. Ticagrelor is oral year investigational antiplatelet treatment to reduce unfavourable major cardiac vents in patients with acute coronary syndrome. The proposed trade name for ticagrelor is Brilinta, which is yet to [...] Post from: (c)Autor:...
+Vote!
Medical News Today (Free subscription) | 22/11/2009
AstraZeneca announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.
3Vote!
Getting Better (Free subscription) | 21/11/2009
In yet another article addressing the war on cancer, The New York Times today tackles cancer prevention, focusing on alternative and mainstream Pharma products marketed to reduce the risk for cancer. While author Gina Kolata seems to have done her homework when it comes to the failure of alternative medicine to prevent cancer, she has missed the story completely when it comes to telling why the medical...
5Vote!
Connecting the Dots in the New World Order (Free subscription) | 21/11/2009
Putting aside its concerns, AstraZeneca would continue its relationship with Reinstein, paying him $490,000 over a decade to travel the nation promoting its best-selling antipsychotic drug, Seroquel. In return, Reinstein provided the company a vast customer base: thousands of indigent, mentally ill residents in Chicago-area nursing homes. During this period, Reinstein also faced accusations that he...
3Vote!
PR News Wire (Free subscription) | 21/11/2009
BOSTON, Nov. 20 /PRNewswire/ -- The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against AstraZeneca Pharmaceuticals (NYSE: AZN).
+Vote!
PR News Wire (Free subscription) | 20/11/2009
WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6 that AstraZeneca will provide free medicines to the city's Health Centers to help uninsured Philadelphians access both the medical care and medications they need.
3Vote!
The Legal Reader (Free subscription) | 20/11/2009
If so, I foresee a lot of money being spent by both sides to retain local counsel… Nov. 19 (Bloomberg) -- AstraZeneca Plc may face as many 6,000 trials of lawsuits claiming its antipsychotic drug Seroquel causes diabetes after a...
3Vote!
SeekingAlpha.com (Free subscription) | 20/11/2009
Mike Havrilla submits: On 11/19/09, AstraZeneca (NYSE: AZN ) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. This submission is based on...
3Vote!
Fiercebiotech (Free subscription) | 19/11/2009
AstraZeneca today announced it has submitted an NDA to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is Brilinta, pending approval from the FDA. Release
+Vote!
cardiobrief.org (Free subscription) | 19/11/2009
AstraZeneca has submitted its new drug application to the FDA for its highly promising new antiplatelet agent, ticagrelor (Brilinta). (See press release below.) Two phase II studies presented at the AHA earlier this week shed more light on the drug. The Onset-Offset study showed that ticagrelor had a more rapid and sustained antiplatelet effect than clopidogrel, followed [...]
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 19/11/2009
AstraZeneca (NYSE: AZN) closed yesterday at $45.47. So far the stock has hit a 52-week low of $29.96 and 52-week high of $47.61. AstraZeneca stock has been showing support around 45.09 and resistance in the 45.83 range. Technical indicators for the stock are Bullish and S&P gives AZN a neutral 3 STAR (out of 5) hold rating. AZN appears on the Investors Observer Hedged Dividend Income list. For...
Videos